Tritonix.ai

News / Taiwan / cnyes

Evercyte August Revenue Hits Yearly High of NT$110 Million

Health Technology · Biotechnology · cnyes · 2026-09-01

6712

Taiwan-based cell therapy firm Evercyte reported an August revenue of NT$110 million, marking a year-to-date high driven by robust growth in CDMO and cell services.

What Happened

Revenue Performance: Evercyte (6712) announced August revenue of NT$110 million, representing a 10.47% monthly increase and a 21.1% year-on-year growth. This achievement marks the company's highest monthly revenue for the year, with cumulative revenue for the first eight months reaching NT$669 million.

Market Trends: The company highlighted the recent clinical success of mRNA-based cancer treatments, which validates the commercial potential of mRNA technology beyond infectious diseases. Evercyte is leveraging these industry trends to enhance its own technological capabilities.

R&D Strategy: Evercyte's lead pipeline candidate, CAR001, utilizes a differentiated strategy focused on off-the-shelf, standardized cell therapy. The project has successfully completed Phase 1 clinical trials and is currently advancing through Phase 2a to gather critical safety and efficacy data.

Future Outlook: Moving forward, the company plans to maintain its momentum by integrating CDMO services with its proprietary drug pipelines, including EXO001 and dEV001. Management remains committed to advancing its AI and exosome-based manufacturing platforms to capture emerging market opportunities.

Read original

More in Health Technology

Yuhan Corp. Secures 131.1 Billion Won API Supply Deal with Global Pharma

Health Technology · yonhap_finance · 2026-09-01

Yuhan Corp. has signed a 131.1 billion won contract to supply active pharmaceutical ingredients to an undisclosed global pharmaceutical company through 2028.

000100

Ever Supreme Bio Tech Reports Strong August Revenue Growth as CAR001 Clinical Trials Advance

Health Technology · economic_daily · 2026-09-01

Ever Supreme Bio Tech announced an 11% monthly revenue increase for August, driven by steady demand for cell therapy services and CDMO operations while advancing its CAR001 cancer treatment.

6712

DB Asset Management Launches Active ETF Focused on Innovative Drug Developers

Health Technology · yonhap_finance · 2026-09-01

DB Asset Management has listed a new active ETF targeting promising South Korean companies specializing in innovative drug development and pipelines.

Latest in Taiwan

Taishin and Shin Kong Financial Shares Surge Toward $40 Mark Amid Merger Optimism

Finance · economic_daily · 2026-09-01

Taishin Financial and Shin Kong Financial see their share prices climb toward the $40 level as the market anticipates strong synergies from their merger.

LITE-ON Semiconductor Subsidiary Sees Volume-Driven Surge to Limit Up

Electronic Technology · economic_daily · 2026-09-01

LITE-ON's share price hit the daily limit with heavy volume, leaving a long lower shadow that has sparked market speculation regarding potential positive news.

Dingying Investment Holdings Hits Limit Up as Foreign Investors Pivot to Buying

Electronic Technology · economic_daily · 2026-09-01

Dingying Investment Holdings saw its share price surge to the daily limit on high volume, with foreign investors shifting from net sellers to buyers.

Six Stocks Including GSEO Face Trading Restrictions Starting Tomorrow

Electronic Technology · cnyes · 2026-09-01

Taiwan's stock exchanges have placed six companies, including GSEO and Xintec, under trading restrictions due to excessive volatility, effective tomorrow.

3374, 3406, 3629, 6805, 6933, 8358